Articles By Jack Cush, MD
Supreme Court Declines Biosimilar Patent Dispute
The U.S. Supreme Court has declined to hear a case over whether companies that make biosimilar drugs must wait six months after federal approval before they bring them to the market.
Read Article
Random Drug Levels and Anti-Drug Antibodies Predict Rheumatoid Outcomes
Researchers from Manchester, UK have reported the results of their BRAGGSS study showing that certolizumab (CZP) random drug levels and anti-drug antibody (ADAbs) levels can predict optimal outcomes in CZP treated rheumatoid arthritis patients.
Read Article
CDC Report on Smoking and Smokeless Tobacco
Combustible and smokeless tobacco use causes adverse health outcomes, including cardiovascular disease and multiple types of cancer. Cigarette consumption in the United States has declined overall since the 1960s, but consumption of other tobacco products has not.
Read Article
Rituximab May Reduce Mortality Risk in Rheumatoid Lung Disease
While it is known that rheumatoid arthritis (RA) patients with interstitial lung involvement is associated with severe seropositive disease and is associated with an increased mortality.
Read Article
RheumNow Week in Review – 9 December 2016
Dr. Jack Cush reviews highlights from this week on RheumNow.com.
Read Article
CanVasc Recommendations for ANCA-Associated Vasculitis
ANCA associated vasculitis (AAV) has undergone considerable study and advances in the last few years.
Read Article
Physicians Still Over-Prescribe Antibiotics, Narcotics and Opioids
A study by the American College of Physicians (ACP) found that physicians continue to prescribe treatments that offer little benefit to patients, despite the advice of clinical guidelines.
Read Article
Key Lessons from the TNF Inhibitor Head-to-Head EXXELERATE Study
The EXXELERATE study is featured prominently in Lancet this week. In some ways, this represents a landmark negative trial that rheumatologists should review and be aware of.
Read Article
Is ABT-494 the Next JAK Inhibitor?
Tofacitinib may well be joined by a new once daily JAK inhibitor, baricitinib in the next few months.
Read Article
The RheumNow Week in Review – 2 December 2016
Dr. Cush highlights reports from this week on RheumNow.com.
Read Article
